Patents by Inventor Paul Pumpens
Paul Pumpens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220305131Abstract: The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.Type: ApplicationFiled: April 6, 2022Publication date: September 29, 2022Inventors: Martin BACHMANN, Andris ZELTINS, Paul PUMPENS
-
Patent number: 11324836Abstract: The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.Type: GrantFiled: November 26, 2019Date of Patent: May 10, 2022Assignee: SAIBA AGInventors: Martin Bachmann, Andris Zeltins, Paul Pumpens
-
Publication number: 20200155699Abstract: The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.Type: ApplicationFiled: November 26, 2019Publication date: May 21, 2020Inventors: Martin BACHMANN, Andris ZELTINS, Paul PUMPENS
-
Patent number: 10532107Abstract: The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.Type: GrantFiled: October 20, 2015Date of Patent: January 14, 2020Assignee: SAIBA GMBHInventors: Martin Bachmann, Andris Zeltins, Paul Pumpens
-
Patent number: 9950055Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: GrantFiled: January 23, 2014Date of Patent: April 24, 2018Assignee: KUROS BIOSCIENCES AGInventors: Martin F. Bachmann, Tazio Storni, Patrik Maurer, Alain Tissot, Katrin Schwarz, Edwin Meijerink, Gerd Lipowsky, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Publication number: 20170312371Abstract: The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.Type: ApplicationFiled: October 20, 2015Publication date: November 2, 2017Applicant: SAIBA GMBHInventors: Martin BACHMANN, Andris ZELTINS, Paul PUMPENS
-
Publication number: 20150030620Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: ApplicationFiled: January 23, 2014Publication date: January 29, 2015Applicant: CYTOS BIOTECHNOLOGY AGInventors: MARTIN F. BACHMANN, Tazio STORNI, Patrick MAURER, Alain TISSOT, Katrin SCHWARZ, Edwin MEIJERINK, Gerd LlPOWSKY, Paul PUMPENS, Indulis CIELENS, Regina RENHOFA
-
Patent number: 8691209Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: GrantFiled: November 10, 2011Date of Patent: April 8, 2014Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Tazio Storni, Patrik Maurer, Alain Tissot, Katrin Schwarz, Edwin Meijerink, Gerd Lipowsky, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Publication number: 20140056933Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.Type: ApplicationFiled: July 22, 2013Publication date: February 27, 2014Inventors: Wolfgang Renner, Martin F. Bachmann, Indulis Cielens, Conrad Johannes Coester, Klaus Dietmeier, Sebastian Fuchs, Vania Manolova, Patrik Maurer, Paul Pumpens, Regina Renhofa, Alain Tissot, Yu Zou
-
Patent number: 8574564Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.Type: GrantFiled: October 8, 2009Date of Patent: November 5, 2013Assignee: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Martin F. Bachmann, Indulis Cielens, Conrad Johannes Coester, Klaus Dietmeier, Sebastian Fuchs, Vania Manolova, Patrik Maurer, Paul Pumpens, Regina Renhofa, Alain Tissot, Yu Zou
-
Publication number: 20120301499Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: ApplicationFiled: November 10, 2011Publication date: November 29, 2012Applicant: CYTOS BIOTECNOLOGY AGInventors: MARTIN BACHMANN, TAZIO STORNI, PATRIK MAURER, ALAIN TISSOT, KATRIN SCHWARZ, EDWIN MEIJERINK, GERD LIPOWSKY, PAUL PUMPENS, INDULIS CIELENS, REGINA RENHOFA
-
Publication number: 20100303846Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.Type: ApplicationFiled: October 8, 2009Publication date: December 2, 2010Applicant: Cytos Biotechnology AGInventors: Wolfgang A. RENNER, Martin F. BACHMANN, Indulis CIELENS, Conrad Johannes COESTER, Klaus DIETMEIER, Sebastian FUCHS, Vania MANOLOVA, Patrik MAURER, Paul PUMPENS, Regina RENHOFA, Alain TISSOT, Yu ZOU
-
Publication number: 20100092508Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: December 22, 2008Publication date: April 15, 2010Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Patent number: 7494656Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: November 20, 2006Date of Patent: February 24, 2009Assignee: Cytos Biotechnology AGInventors: Martin Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Publication number: 20080292652Abstract: The present invention is in the fields of medicine, immunology, virology and molecular biology. The present invention provides a composition comprising a modified virus-like (VLP) particle derived from RNA bacteriophage AP205. The invention also provides a process for producing the aforementioned VLP. The modified VLP disclosed in the present invention is useful in the production of compositions for inducing immune responses for the prevention or treatment of diseases, disorders including infectious diseases, allergies, cancers and drug addiction. Moreover, the modified VLP disclosed in the present invention is, in particular, useful to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: September 21, 2005Publication date: November 27, 2008Applicant: CYTOS BIOTECHNOLOGY AGInventors: Martin F Bachmann, Alain Tissot, Gary Jennings, Regina Renhofa, Paul Pumpens, Indulis Cielens
-
Publication number: 20070184068Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.Type: ApplicationFiled: December 14, 2006Publication date: August 9, 2007Applicant: Cytos Biotechnology AGInventors: Wolfgang Renner, Martin Bachmann, Indulis Cielens, Conrad Coester, Klaus Dietmeier, Sebastian Fuchs, Vania Manolova, Patrik Maurer, Paul Pumpens, Regina Renhofa, Alain Tissot, Yu Zou
-
Publication number: 20070128219Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: November 20, 2006Publication date: June 7, 2007Applicant: Cytos Biotechnology AGInventors: Martin Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Patent number: 7138252Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: July 14, 2003Date of Patent: November 21, 2006Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Publication number: 20040076611Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: July 14, 2003Publication date: April 22, 2004Inventors: Martin F. Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Publication number: 20040054139Abstract: A protein is provided comprising hepatitis B core antigen (HBcAg) wherein one or more of the four arginine repeats has been deleted, said protein comprising the C-terminal cysteine of HBcAg. The deleted region may be replaced by an epitope from a protein other than HBcAg, in which case the HBcAg acts as a carrier to present the epitope to the immune system. The chimeric protein is useful in prophylactic and therapeutic vaccination of a host, for example against hepatitis B virus.Type: ApplicationFiled: March 11, 2003Publication date: March 18, 2004Inventors: Mark Page, Jin-Li Li, Paul Pumpens, Galina Borisova